Sarcoma | Clinical

Adjuvant Imatinib Confirmed Beneficial for RFS in High-Risk Gastrointestinal Stromal Tumors

February 20, 2021

Adjuvant imatinib has demonstrated significant improvement in relapse-free survival over a 2-year period and a mild trend toward long-term improvement in failure-free survival as treatment of patients with high-risk gastrointestinal stromal tumors, according to 9.1-year follow-up results from a randomized phase 3 study.

Invasive GIST Originating in the Stomach/Small Intestine Is More Common in Men, Study Shows

February 19, 2021

Men appear to be more likely than women to have invasive gastrointestinal stromal tumors originating in the stomach and small intestines. For treatment, an expert says that combined surgery and systemic therapy demonstrates the best outcomes.

Improved Safety Measures Mark Newest Treatments in Soft Tissue Sarcoma

January 26, 2021

In early 2020, the treatment paradigm of soft tissue sarcoma had 3 notable advancements with the FDA approving therapies in epithelioid sarcoma, Kaposi sarcoma, and gastrointestinal stromal tumors.

FDA Grants Orphan Drug Designation to Ilixadencel to Treat Soft Tissue Sarcoma

January 26, 2021

An Orphan Drug Designation was granted by the FDA to ilixadencel as use for the treatment of patients with soft tissue sarcoma.

FDA Grants Orphan Drug Designation to Annamycin in Soft Tissue Sarcomas

January 04, 2021

The FDA has granted an Orphan Drug Designation to annamycin for the treatment of patients with soft tissue sarcomas.

Expert Speaks to Impact of COVID-19 in the Community Oncology Setting, Vaccine Excites Field

December 16, 2020

In an interview with Targeted Oncology, Michael J. Wagner, MD, discussed findings from a single-center experience in Seattle managing patients with sarcoma during the COVID-19 pandemic.

Novel Agent ADP-A2M4 Elicits Durable Response in Synovial Sarcoma

November 24, 2020

The investigational engineered SPEAR T-cell agent, ADP-A2M4, induced durable responses in patients with synovial sarcoma, according to updated results from the phase 1 clinical trial presented during the Connective Tissue Oncology Society Annual Meeting.

Phase 1 Trial Exhibits Positive Interim Results in Chondrosarcoma

November 13, 2020

Treatment with the investigation agent INBRX-109 induced responses and decreased the tumor burden in a cohort of patients with chondrosarcoma, according to interim efficacy and safety findings a phase 1 trial in patients with chondrosarcoma, Inhibrx, Inc announced in a press release.

Selinexor Meets PFS Primary End Point in Phase 3 Study of Advanced Unresectable Dedifferentiated Liposarcoma

November 03, 2020

Selinexor induced a statistically significant reduction in the risk of disease progression or death compared with placebo as treatment of patients with advanced unresectable dedifferentiated liposarcoma.

FDA Grants Orphan Drug Designation to Devimistat for Soft Tissue Sarcoma

October 29, 2020

The FDA has granted an Orphan Drug designation to CPI-613 for the treatment of soft tissue sarcoma.